Anzu Partners, a private equity firm, led a $15m Series A round in Codetta Biosciences, a biotechnology company, with participation from Genoa Ventures and VC23. "This Series A funding will support our start-up infrastructure and accelerated development of Codetta’s technology platform. Our strategy is to develop an integrated platform that redefines multi-omic and sets a new standard of capability in the mid-plex translational research and clinical markets," TJ Johnson, Codetta Biosciences CEO.